Table 1.

Baseline characteristics of patients with IgA nephropathy

All Patients
(N=985)Nephrotic Syndrome
(n=100)Non-Nephrotic Syndrome
(n=885)P
Age (yr)37.7±12.839.5±15.037.4±12.50.12
Male sex, n (%)459 (46.6)44 (44.0)412 (46.6)0.83
Hypertension, n (%)125 (12.7)20 (20.0)105 (11.9)0.03
Diabetes, n (%)14 (1.4)4 (2.9)10 (1.1)0.08
Hepatitis B surface antigen positivity, n (%)31 (3.1)7 (7.0)24 (2.7)0.04
Systolic BP (mmHg)123.7±34.8131.9±15.1122.1±34.80.01
Diastolic BP (mmHg)76.8±8.981.1±10.376.2±8.7<0.001
Mean arterial BP (mmHg)92.4±14.398.0±10.991.8±14.5<0.001
Laboratory measurements
 24-h protein excretion (g/d)1.31 (0.0–16.10)5.80 (3.67–16.10)1.5 (0.0–3.40)<0.001
 random UPCR (g/g) 1.05 (0.01–18.20)5.74 (3.50–18.20)0.98 (0.01–3.74)<0.001
 SCr (mg/dl)1.0±0.61.2±0.40.9±0.3<0.001
 eGFR (ml/min per 1.73 m2)84.1±39.169.4±17.588.5±32.5<0.001
 serum albumin (g/dl)4.1±0.72.8±0.64.2±0.5<0.001
 total cholesterol (mg/dl)190.5±51.3267.0±76.2181.8±39.1<0.001
Follow-up duration (mo)45.2 (9.0–134.6)43.1 (9.0–107.8)47.1 (10.0–134.6)0.06
Treatments, n (%)<0.001
 none197 (20.0)0 (0.0)197 (22.3)
 ACEi or ARB778 (79.0)95 (95.0)683 (77.2)
 dual blockades10 (1.0)5 (5.0)5 (0.5)
 corticosteroids144 (14.6)65 (65.0)79 (8.9)
  • All data are expressed as mean ± SD and median (range). UPCR, urinary protein-to-creatinine ratio; SCr, serum creatinine; eGFR, estimated GFR; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.